Q522--Pharmaceutical STL PLUVICTO
SAM.GOV Due: June 18, 2025 at 08:00 PM UTC
In-Active Sources Sought Source Url

Summary

The opportunity Q522--Pharmaceutical STL PLUVICTO is a sources sought notice issued by the VA Heartland Network 15, seeking qualified contractors to provide the radiopharmaceutical agent Pluvicto for the St. Louis VA Medical Center. This notice is primarily for market research purposes and aims to identify potential Service-Disabled Veteran Owned Small Businesses, Veteran Owned Small Businesses, and other small businesses capable of supplying this specialized pharmaceutical. The work involves the provision of a proprietary radiopharmaceutical agent indicated for the treatment of prostate cancer, specifically for patients with PSMA positive metastatic castration resistant prostate cancer. Contractors with expertise in pharmaceutical preparation manufacturing and experience in handling radiopharmaceuticals are encouraged to respond to this notice, as it may lead to a future solicitation for a five-year blanket purchase agreement (BPA).
Description
The purpose of this sources sought announcement is for market research to make appropriate acquisition decisions and to gain knowledge of potential qualified Service-Disabled Veteran Owned Small Businesses, Veteran Owned Small Businesses, 8(a), HubZone and other Small Businesses interested and capab
Entities
VADO
Department of Veterans Affairs
NAICS
325412
Set Aside
None
Place of Performance
St. Louis VA Medical Center , St. Louis 63125
Point of Contact
Full Name Email Phone Type
Michael Murphy [email protected] 913-946-1963 primary
Attachments
  • 36C25525Q0426.docx